发明名称 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
摘要 The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of cytochrome c and insulin-like growth factor IA as diagnostic and prognostic biomarkers in renal injuries.
申请公布号 US9417250(B2) 申请公布日期 2016.08.16
申请号 US201514738904 申请日期 2015.06.14
申请人 Astute Medical, Inc. 发明人 Anderberg Joseph;Gray Jeff;McPherson Paul;Nakamura Kevin
分类号 G01N33/53;G01N33/68 主分类号 G01N33/53
代理机构 代理人 Whittaker Michael A.
主权项 1. A method for evaluating renal status in an adult subject for a predisposition of a future acute renal injury, comprising: obtaining a urine sample from the adult subject; performing one or more assays configured to detect by introducing the urine sample obtained from the adult subject into an assay instrument which contacts all or a portion of the urine sample with a binding reagent which specifically binds for detection insulin-like growth factor IA (IGF-IA)(SEQ ID No. 2), and (ii) generates an assay result indicative of binding of insulin-like growth factor IA to the binding reagent; correlating the assay result generated by the assay instrument to the renal status of the adult subject, wherein said correlation step comprises correlating the assay result to one or more of risk stratification, staging, prognosis, classifying and monitoring of the renal status of the subject by using the one or more assay results to assign the adult subject to a predetermined subpopulation of individuals having a known predisposition of a future renal injury within 72 hours of the time at which the urine sample is obtained; and treating the adult subject based on the predetermined subpopulation of individuals to which the adult subject is assigned, wherein the treatment comprises one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying or avoiding procedures that are known to be damaging to the kidney, and modifying diuretic administration.
地址 San Diego CA US
您可能感兴趣的专利